Fmoc-L-lys[C20-otbu-glu(otbu)-aeea-aeea]-OH

Basic information

  • Product Name:Fmoc-L-lys[C20-otbu-glu(otbu)-aeea-aeea]-OH
  • CAS No.:2460751-66-8
  • EINECS No.:-
  • MF:C66H105N5O16

Product Specifications

  • Appearance:off-white or light-yellow paste
  • Specification:98.5%
  • Package:1/5/10/25kgs/drum
  • Supply Capacity:KGS
  • UN number:-
Inquiry

Product Details

CAS No:2460751-66-8

MF:C66H105N5O16

Appearance:off-white or light-yellow paste

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:KGS

Synonyms:Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH;Fmoc-Lys[tBuO-Ara-Glu(AEEA-AEEA)-OtBu]-OH;(25R,52S)-52-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-25-(tert-butoxycarbonyl)-2,2-dimethyl-4,23,28,37,46-pentaoxo-3,32,35,41,44-pentaoxa-24,29,38,47-tetraazatripentacontan-53-oic acid;Fmoc-Lys(tBuO-ICO-Glu(AEEA-AEEA)-OtBu)-OH;Fmoc-Lys Tirzepatide side chain;Semaglutide Fatty Acid Side Chain Intermediate;Fmoc-Lys(AEEA-AEEA-?-Glu(OtBu)-C20-OtBu)-OH;Fmoc Lys[AEEA-AEEA-Y-Glu(OtBu)-C20-otBu]-OH; 2460751-66-8; FMOC-L-LYS[C20-OTBU-GLU(OTBU)-AEEA-AEEA]-OH; (25R,52S)-52-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-25-(tert-butoxycarbonyl)-2,2-dimethyl-4,23,28,37,46-pentaoxo-3,32,35,41,44-pentaoxa-24,29,38,47-tetraazatripentacontan-53-oic acid; Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH; DB-385665; (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[[2-[2-[2-[[2-[2-[2-[[(4R)-5-[(2-methylpropan-2-yl)oxy]-4-[[20-[(2-methylpropan-2-yl)oxy]-20-oxoicosanoyl]amino]-5-oxopentanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]hexanoic acid; Fmoc-Lys[tBuO-Ara-Glu(AEEA-AEEA)-OtBu]-OH; Tirzepatide linker; LHW5PQ8XBY; Tirzepatide Impurity 22; orb3021991; MFCD35146359; TYD-02028; AS-89392; BP-44013; F71059; Fmoc-Lys(tBuO-ICO-Glu(AEEA-AEEA)-OtBu)-OH; Fmoc Lys[AEEA-AEEA-Y-Glu(OtBu)-C20-otBu]-OH; Fmoc-Lys(AEEA-AEEA-gamma-Glu(OtBu)-Eic-OtBu)-OH


Product application:Fmoc-L-lys[C20-otbu-glu(otbu)-aeea-aeea]-OH,2460751-66-8,Tirzepatide side chain,Fmoc-Lys(C20-OtBu-Glu(OtBu)-AEEA-AEEA)-OH,Tirzepatide intermediate,GLP-1 receptor agonist raw material,GIP/GLP-1 dual agonist synthon,Long-acting fatty acid side chain,Diacid fatty acid modifier,Eicosanedioic acid peptide linker,AEEA-AEEA spacer,Protected lysine building block,Solid phase peptide synthesis SPPS building block,High purity Tirzepatide side chain 99%,Low isomer Fmoc-L-lys side chain,CAS 2460751-66-8 supplier,Tirzepatide side chain manufacturer China,Suzhou Health Chemicals peptide intermediates,Tirzepatide side chain wholesale bulk export

 

Fmoc-L-lys[C20-otbu-glu(otbu)-aeea-aeea]-OH is widely utilized across commercial manufacturing of next-generation therapeutic long-acting peptides, industrial API process synthesis of dual GIP and GLP-1 receptor agonists, metabolic disorder drug discovery campaigns, segment-condensation peptide assembly, and site-specific bioconjugation technologies in modern biopharmaceutical sectors. In peptide process development and commercial active ingredient manufacturing, universally designated across pharmaceutical science as Tirzepatide side chain, it functions as the quintessential, pre-assembled building block for synthesizing Tirzepatide; its molecular framework integrates a mono-tert-butyl-protected C20 eicosanedioic acid tail, two hydrophilic 8-amino-3,6-dioxaoctanoic acid (AEEA) spacers, and a gamma-linked L-glutamic acid unit onto the epsilon-amino moiety of an N-alpha-Fmoc-protected L-lysine core; this structure allows direct, single-step coupling onto the growing peptidyl resin at Lys20 during automated solid-phase peptide synthesis (SPPS), overcoming the severe steric hindrance, incomplete acylation, and intractable deletion impurities associated with stepwise on-resin assembly of long-chain fatty diacid architectures; as a consequence, it shortens total synthesis cycle durations while elevating crude peptide purity and commercial crystallization yields; when fully deprotected in the mature Tirzepatide peptide, this engineered side-chain motif promotes reversible, high-affinity non-covalent binding to circulating human serum albumin, shielding the therapeutic sequence from renal clearance and dipeptidyl peptidase-4 (DPP-4) enzymatic degradation to sustain an extended in vivo terminal half-life that facilitates once-weekly clinical administration regimens; furthermore, in investigational multi-agonist incretin engineering, Fmoc-L-lys[C20-otbu-glu(otbu)-aeea-aeea]-OH delivers consistent coupling kinetics and structural stability across demanding industrial bioprocessing environments.